drugset / Trial / NCT00900588
Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescents
Phase 2
Completed
Sinovac Biotech Co., Ltd
Centers for Disease Control and Prevention, China · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A single center, stratified, randomized and double-blind phase II clinical trial was conducted in adolescents to evaluate the safety and immunogenicity of a split-virion pandemic influenza A vaccine (H5N1).
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14) | Vaccine | 5 ug | — |
| Subject | split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14) | Vaccine | 10 ug | — |
| Subject | split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14) | Vaccine | 15 ug | — |
| Subject | split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14) | Vaccine | 30 ug | — |